TriangleNCT03353753 · OUTCOME
Quality of Life & Disease-Related Symptoms - EuroQol Visual Analogue Scale
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Units on a Scale
- Interval / dispersion
- Standard Deviation
- Time frame
- From the date of randomization (Baseline) to Cycle 2 Day 1 (Month 2)
What was measured
Change from baseline in EuroQol Visual Analogue Scale. For the ripretinib arm the minimum and maximum for the outcome were -43 to 91; the placebo arm had a range of -68 to 23. The higher value represents a higher quality of life in disease-related symptoms.
Analysis population: ITT Population
Groups in this outcome
Ripretinib
Ripretinib (150 mg) once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).
Placebo
Placebo once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).
| Group | Source count |
|---|---|
| Ripretinib | 85 |
| Placebo | 43 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ripretinib | 3.7 | 20.36 | Not reported | Not reported | Not reported |
| Placebo | -8.9 | 19.31 | Not reported | Not reported | Not reported |
Source statistical analyses
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.004
- statistical Method
- t-test, 2 sided
Complete source fields
- analyses
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.004
- statistical Method
- t-test, 2 sided
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 20.36
- value
- 3.7
- group Id
- OG001
- spread
- 19.31
- value
- -8.9
- denoms
- counts
- group Id
- OG000
- value
- 85
- group Id
- OG001
- value
- 43
- units
- Participants
- description
- Change from baseline in EuroQol Visual Analogue Scale. For the ripretinib arm the minimum and maximum for the outcome were -43 to 91; the placebo arm had a range of -68 to 23. The higher value represents a higher quality of life in disease-related symptoms.
- dispersion Type
- Standard Deviation
- groups
- description
- Ripretinib (150 mg) once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).
- id
- OG000
- title
- Ripretinib
- description
- Placebo once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).
- id
- OG001
- title
- Placebo
- param Type
- MEAN
- population Description
- ITT Population
- reporting Status
- POSTED
- time Frame
- From the date of randomization (Baseline) to Cycle 2 Day 1 (Month 2)
- title
- Quality of Life & Disease-Related Symptoms - EuroQol Visual Analogue Scale
- type
- SECONDARY
- unit Of Measure
- Units on a Scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice